Allesgen Alternative Treatment

Three Phases of Experiments

Phase I: Tumor cell lines experiment
6 cancer cell lines were used for this research. Cancer cell lines from breast, lung, colon, ovarian, cervical and uterine origins were cultured and Allesgen in an amount of  0.2, 0.4, 0.6, 0.8, 1.0mg/ml concentration were administered in cell cultural solutions. The result are outstanding: 50% of all cancer cell lines were eliminated in the concentration of Allesgen in amount of  0.4 to 0.6 mg/ml, and more than 90% of cancer cell lines were eliminated at the concentration of 1mg/ml.

Phase II: Animal Experiment (Example 3)
Allesgen inhibits cancer cell growth in vivo on experiemntal animal.
Allesgen intraperitoneal administration to experimental animal.

[033] 14 experimental animals of  4 to 6 week old white rabbits each weighting 1 to 1½ pounds were fed under a condition of 23+_3 degree C, relative humidity of 45+_5 % and photoperiod of 12 light/12 dark. The rabbits were divided into seven groups of 2 heads each and were fed with Harlan-Taklad rabbit diet TD-1376 containing moisture 12%, crude protein 16%, crude fat 2%, crude fiber 15% , ash 8%, and 47% of nitrogen free substances.
[034] The rabbits were fed for 3 weeks with free access to the diet and water. Body weight was recorded every 7 days, and records were analyzed. All rabbits showed a normal growth rate with no significant differences among the 7 groups in regard to the diet ingestion amount or the body weight gain. The cancer cell lines were injected into six groups of the rabbits, that is 2 heads each group with 2 heads serving as controls (without tumor cell injection). The cancer cell lines were developed from Example-2. Each head was injected 0.5ml of different cell line fluid intraperitoneally, prefer in the peritoneum layer, then the rabbits were fed the same diet for 3-4 weeks until a tumor grew in the peritoneum. The size and location of the tumors were recorded. When the tumors reached 3-5mm diameter in size, Allesgen in the amount of 25.0mg/ml in normal saline with 100mg of vitamin C (to keep the solution acidified), one ml of Allesgen was injected into the six different group of rabbits, the Allesgen were given twice a week for 8 weeks.
[035] After 8 weeks of treatment, the rabbits were anesthetized with injections of ketamine 75mg/kg in the femoral muscle and sacrificed. Blood samples were collected from the heart of each rabbit to determine the blood analysis which  consisted of: complete blood count (CBC), Chemistry-7 and 24, (including liver and renal function tests), lipid profiles (including total cholesterol, HDL, LDL, VLDL, and triglycerides), coagulation factors consisting of; prothrombintime (PT), partial thromboplastin time (PPT), and immune-globulin –E. All the laboratory tests were analyzed, and indicated no differences among or within each groups. All laboratory blood analyses were performed on rabbits of all 7 groups. The results were tested using student t-test and Microsoft Excel-7 programs. The results are depicted in Table-II.
[036] Table–II, The table presents blood analysis of the rabbits of 6 different groups which were treated with Allesgen after inoculation of cancer cell lines. Control group; TC (183.3+_50.2mg/dl ), TRG (110+_40.6mg/dl), HDL (45.6+_20.4mg/dl), SGOT (38.6+_6.2u/l), SGPT (62.5 +_6.5u/l), GGTP (8+_ 2.4u/l ), WBC (6.8 +_ 2.0k/ul), Hb; (12.3+_2.2gm/dl). Bromelainase treated groups; TC (175.6+_ 36.8mg/dl), TRG (92.6 +_ 38.8mg/dl), HDL (43.6 +_16.5mg/dl), SGOT (110.8 +_30.7u/l ), SGPT (71.2 +_3.8u/l ), GGTP (7+_1), WBC (7.3+_ 2.2k/ul), Hb (11.9+_1.9gm/dl). TC; Total Cholesterol, TRG: Triglycerides, WBC: White Blood Cell, HDL; High Density Lipoprotein, SGOT; Serum Glutamo-Oxalic Transferase, SGPT; Serum Glutamo-PyruvicTransferase, Hb; Hemoglobin.
[036] The internal organs from the rabbits sacrified in this sample including lung, heart, liver, kidney, muscle, omentum, intestine, stomach bladder and pancreas were visual examined and showed no abnormalities. One half of each organ was frozen, and the other half was fixed with 10% neutral buffered formalin for 24 hours. Then the fixed organs were washed with tap waterand stepwise dehydrated with 70%, 80%, 90% and 100% ethanol and then embedded in paraffin using Shandon-Histocentre-2. The embedded organ blocks were sectioned in 4mm thickness with a microtome (McBain, M 820, American Optical Co. USA) and stained with hematoxylin and eosin stain (H.E. stain). The stained specimens were made transparent with xylene, and mounted with permount on microslides. There were no pathological abnormalities or lesions under microscopic examination. All the specimens collected from six group of rabbits showed no evidence of persistent disease or cancer cells.

Therefore, we concluded that Allesgen can served as a potent chemotherapeutic agent in various types of cancer treatment in experimental animal without side effects.

Phase III: Human Volunteer Experiment (Example 4)
Allesgen oral administration to inhibit tumor growth in humans.
Allesgen oral administration to late stage cancer patients.

[037] Twenty-four volunteers were divided into 6 groups (4 in each group) and 6 persons served as a control group (no Allesgen treatment). All were in their 4th and 6th decades with various types of cancers including breast, lung, colon, ovarian, cervical and uterine origins. All were in either Stage III or Stage IV. (The cancers had metastasized widely either to lung, liver, bladder or rectum). All had been treated with either radiation or chemotherapy after surgery but experienced no positive results. The Allesgen was administered in doses of 50GDU/kg based on 60kg of body weight. That is 5,000 to 6,000GDU/day divided into two doses. Patients were monitored with bi-weekly blood tests; consisting complete blood counts, chemistry-7, chemistry-24, kidney and liver function tests, tumor markers, coagulation factors, and X-ray or CT scan in appropriate areas to determine the size of the tumors. There were no abnormalities in all the blood tests, no anemia, no leucopenia, no thromcytopenia, no abnormal kidney nor liver function tests. Tumor markers decreased; and tumors shrunk in size on the X-ray or CT scan measurement. Patients’ lifestyles become manageable and improved considerably. The treatment periods varied from 6 to 12 months. At this report no patients in the treatment group have expired. However, all patients in control group, who had not wished to be treated, succumbed to their related cancers in 6-12 months.
[038] (Step-A) After blood samples were collected and allowed to stand for 2 hours, they were centrifuged at 4000rpm for 10 minutes. The superantants were separated and stored in a deep freeze before analysis. The chemistry analysis was carried out by blood chemistry analyzer to determine the changes in total cholesterol, HDL, LDL, triglycerides, liver function tests (such as SGOT, SGPT, G-GPT), renal function tests, and coagulation factors (PT, PTT). All results were tested with student t-test and Microsoft Excel-7.0 program. The results are depicted in Table-III, which depicts the blood analysis of 24 volunteers suffering from various types of cancer with Allesgen oral therapy. TC; (210.3+_30.2mg/dl ), TRG; (165.5 +_ 28.3mg/dl), HDL; (43.3 +_ 22.2mg/dl), SGOT ; (34.7+_6.2 u/l),  SGPT; (63.3+_5.6 u/l), GGTP; (7.2+_ 2.1 u/l) WBC; (6.7 +_ 2.8 k/ul), Hb; (12.3+_ 2.1gm/dl)

Therefore, we concluded that the treatment of these various represented types of cancers for prolonged periods with ALLESGEN are effective and without side effects.

Action Mechanism:
1) Fibrinolytic effect: lysis of fibrin of cellular membrane
2) Anti-platelet aggregation: prevents tumor cells from invasion to vascular endothelial wall and surrounding tissues
3) Inhibit tumor cell growth: probably due to T-Cell secretes of TNF (tumor necrotizing factor)
4) Anti-tumor genesis: Inducing Cellular surface antigen TCRS/ CD2, TCRS/CD3 of T-cells and Mononuclear cells and increase Cellular outpour secretion of  Interlukin I-B 13,000pg/ml / 10^6 cells (400 folds production), II-6, 23,000pg/ml/ 10^6 cells (650 folds production), II-8, and TNF 1500pg/ml /10^6 cells (tumor necrotizing factor, 43 folds production) to eliminate tumor cellular surface antigen of CD44, CD45, and CD47 and induce lysis of tumor cell membranes.
5) Anti-De-Differentiation: change DNA of  the abnormal tumor cell back to DNA of the normal cells
6) Anti-metastastic effect: T-cells and Mononuclear cells secretion of cytotoxic cellular kinases protein enzymes through (A) The first signal is generated by the T–Cell Receptors / CD3 (TCRS/CD3, TCRS/CD2) complex after engagement with antigen peptide presented by the Major Histocompatiblility Complex (MHC) expressed on Antigen Presenting Cells (APC). (B) The second pathway is generated by ligation of CD28 receptors on T-cells with the B-7 family of ligands on APC, then transducting receptor initiated signals to the nucleus is the family of Mitogen Activating Protein Kinases (MAPK).

Allesgen enzyme includes:
Comosain (Comosalin)
Bromelainase (Bromelinase)
Bromelainase F9-A
Bromelainase F9-B
Bromelainase Substrate B
Bromelainase Substrate A
Bromelainase Substrate B1-5 (SBB1-5)

Components of Enzymes: All of the enzymes contain both glycogen and polypeptides components. Their polypeptides are similar but only different in sugar components. Their polypeptides are similar to Gastric juice – Peptin, and intestinal juice- Trypsin, which resisted to digestion when administered by an oral route and will be absorbed as enzymes instead of amino acid.